An issue of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) bonds rose 5.3% as a percentage of their face value during trading on Thursday. The debt issue has a 7.875% coupon and is set to mature on September 1, 2023. The bonds in the issue are now trading at $97.75 and were trading at $93.50 one week ago. Price moves in a company’s bonds in credit markets sometimes predict parallel moves in its stock price.
A number of equities analysts recently commented on AMAG shares. Jefferies Group reaffirmed a “buy” rating and set a $16.00 price target on shares of AMAG Pharmaceuticals in a research note on Sunday, November 5th. Janney Montgomery Scott upgraded shares of AMAG Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $16.65 to $45.00 in a report on Thursday. Piper Jaffray Companies reiterated a “hold” rating and set a $15.00 price objective on shares of AMAG Pharmaceuticals in a report on Thursday, January 18th. B. Riley reiterated a “hold” rating and set a $16.00 price objective on shares of AMAG Pharmaceuticals in a report on Tuesday, January 16th. Finally, ValuEngine upgraded shares of AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, January 3rd. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and three have given a buy rating to the stock. AMAG Pharmaceuticals currently has an average rating of “Hold” and an average price target of $21.82.
Shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) opened at $18.50 on Friday. AMAG Pharmaceuticals, Inc. has a twelve month low of $11.93 and a twelve month high of $25.20. The firm has a market cap of $634.97, a PE ratio of -3.04 and a beta of 0.79. The company has a current ratio of 1.59, a quick ratio of 1.48 and a debt-to-equity ratio of 0.94.
COPYRIGHT VIOLATION WARNING: “AMAG Pharmaceuticals (AMAG) Bonds Trading 5.3% Higher” was originally reported by BBNS and is owned by of BBNS. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://baseballnewssource.com/markets/amag-pharmaceuticals-amag-bonds-trading-5-3-higher/1888506.html.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.